Brief: Actinogen Medical Narrow Guidance For Xanamia Phase 2B/3 Alzheimer's Disease Clinical Trial
21/10/2026 02:15
BRIEF-Actinogen Medical Narrow Guidance For Xanamia Phase 2B/3 Alzheimer's Disease Clinical Trial Oct 21 (Reuters) - Actinogen Medical Ltd ACW.AX:
NARROW GUIDANCE FOR TOPLINE RESULTS FOR XANAMIA PHASE 2B/3 ALZHEIMER'S DISEASE CLINICAL TRIAL TO MID-NOV THIS YEAR
Further company coverage: ACW.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinogen Medical
See all newsBrief: Actinogen Medical Narrow Guidance For Xanamia Phase 2B/3 Alzheimer's Disease Clinical Trial
Brief: Actinogen Commences Open-Label Phase Of Xanamia Alzheimer’S Trial And Provides Business Update
Brief: Actinogen Medical Completes A$16.8M Placement And Spp
Brief: Actinogen Medical To Raise A$12.0 Million
Brief: Actinogen Medical Seeks Trading Halt